SCHEMBL293663

SCHEMBL293663

c1ccc(C(c2ccccc2)(c2ccccc2)n2ncc3c(-c4cn[nH]c4)ccnc32)cc1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
AURKA O14965 1/20 0.44
AURKB Q96GD4 1/20 0.44
INCENP Q9NQS7 1/20 0.44
TPX2 Q9ULW0 1/20 0.44
FYN P06241 1/20 0.42
AKT1 P31749 1/20 0.39
AKT2 P31751 1/20 0.39
CYP17A1 P05093 2/20 0.38
CYP1A2 P05177 2/20 0.38
ALK Q9UM73 1/20 0.37
MAP3K14 Q99558 4/20 0.37
BRAF P15056 4/20 0.36
CHEK1 O14757 3/20 0.35
CHEK2 O96017 2/20 0.35
PIM1 P11309 1/20 0.35
GRK2 P25098 1/20 0.35
GSK3B P49841 1/20 0.33
ROCK2 O75116 1/20 0.33
ROCK1 Q13464 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL285259 0.73 CYP17A1 (0.35) CYP17A1CYP1A2
SCHEMBL5956817 0.73 NCF1 (0.39) CYP17A1CYP1A2
SCHEMBL292289 0.73 FEN1 (0.41) CYP17A1CYP1A2PIM1
SCHEMBL2675096 0.71 PRKCQ (0.60) CYP17A1CYP1A2ROCK2ROCK1
SCHEMBL285565 0.70 KDM4E (0.42)
SCHEMBL3430462 0.68 AURKA (0.56) AURKAAURKBINCENPTPX2FYN
SCHEMBL30147790 0.68 AURKA (0.56) AURKAAURKBINCENPTPX2FYN
SCHEMBL285234 0.68 MAP2K1 (0.46) PIM1
SCHEMBL285075 0.68 MAP2K1 (0.35) CYP17A1CYP1A2
SCHEMBL22576893 0.68 TLR8 (0.43) ALK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8541445-B2 Pyrazolopyridines VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-09-24 US disclosed
US-8541445-B2 Pyrazolopyridines VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-09-24 US disclosed
US-8541445-B2 Pyrazolopyridines VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-09-24 US disclosed
US-20120178778-A1 PYRAZOLOPYRIDINES VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-07-12 US disclosed
US-20120178778-A1 PYRAZOLOPYRIDINES VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-07-12 US disclosed
US-20120178778-A1 PYRAZOLOPYRIDINES VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-07-12 US disclosed
EP-2427464-A1 PYRAZOLOPYRIDINES Vertex Pharmaceuticals Incorporated (US) 2012-03-14 EP disclosed
WO-2010129668-A1 PYRAZOLOPYRIDINES VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178778-A1 PYRAZOLOPYRIDINES MAP3K5, MAP4K5, MAP3K20 AURKA 221/4885AURKB 487/4885INCENP 1508/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.